69 results about "Signal peptide" patented technology

Use of an effective amount of the bioactive peptide in the preparation of a medicament for the prevention and / or treatment of hypoxic-ischemic encephalopathy in newborns, wherein the amino acid sequence of the bioactive peptide contains KKNRNKLRRQHSY or a functionally equivalent variant thereof. Optionally, the bioactive peptide further comprises a signal peptide at its N-terminus or C-terminus.

This invention relates to the fields of bioengineering and fermentation engineering, and discloses a genetically engineered *Streptomyces albopictus* strain that produces high levels of ε-polylysine and its fermentation production process. This genetically engineered strain uses *Streptomyces albopictus* strains acclimated to ε-polylysine tolerance as a chassis, and its genome integrates... ppc and dapf Through expression box, heterogeneous asd Expression cassettes, containing secretory signal peptides lysp Fusion expression cassettes and D404A / K499A point mutations pls Expression cassette. The fermentation process employs a two-stage pH control strategy, maintaining a neutral environment during the cell growth phase and adjusting to an acidic environment during product synthesis. This invention improves ε-polylysine yield through a synergistic strategy of enhancing precursor supply, constructing efflux detoxification channels, and increasing synthase activity; combined with an acidic fermentation process, it effectively inhibits product degradation, yielding a high-molecular-weight and highly uniform target product suitable for industrial production.

This document provides novel recombinant polypeptides comprising an endogenous cell protrusion targeting signal peptide and a payload protein, nucleic acid molecules encoding said recombinant polypeptides, pharmaceutical compositions comprising said nucleic acid molecules, and methods of using the same. In some embodiments, the recombinant polypeptide comprises the formula X1-(Y1)a-Z1, wherein X1 is an endogenous signal peptide, Y1 is a peptide linker, and Z1 is a payload protein, wherein a is an integer selected from 0 and 1.

The present disclosure provides a P450 cytochrome enzyme for andrographolide synthesis and its application, belonging to the field of bioengineering. The present disclosure uses Saccharomyces cerevisiae CEN.PK2-1D as a host, and implements knockout of ROX1 and GAL80 genes on the genome, and integrative expression of GGPP synthase encoding gene and CPS diterpene synthase encoding gene at ROX1 site; and implements free expression of ApCPR and CYP71A8 and CYP71D10 both with truncated signal peptides, successfully constructing recombinant S. cerevisiae, and achieving de novo synthesis of 3,15,19-Trihydroxy-8(17),13-ent-labdadiene-16-oic acid. Compared with the blank, a response value of a product peak reaches 1.9*106, and this strategy provides necessary reference for analyzing biosynthetic pathway of andrographolide and using metabolic engineering to synthesize andrographolide and related derivatives thereof.

The present application relates to signal peptides for producing Serratia marcescens-derived nuclease and uses thereof. In particular, the present application relates to a polypeptide comprising a signal peptide and a Serratia marcescens-derived nuclease amino acid sequence, a microorganism comprising said polypeptide, and a method of producing Serratia marcescens-derived nuclease, said method comprising the step of culturing said microorganism. The present application can be used for large-scale production of Serratia marcescens-derived nuclease.

The application belongs to the technical field of animal genetic engineering, and particularly discloses a construction method of C1R gene humanized animal cells and animal models and application thereof. The construction method of the C1R gene humanized animal cells comprises the following steps: introducing a human C1R gene into non-human animal cells, so that the human C1R gene is expressed in the non-human animal cells to produce humanized C1R protein, and meanwhile, the expression of an endogenous C1ra gene in the non-human animal cells is reduced or eliminated. The application preferably adopts CRISPR / Cas9 gene editing technology to accurately insert a genomic sequence encoding a human C1R mature protein into a 2nd exon region of a mouse C1ra gene, while retaining a mouse source promoter, a 5' untranslated region (UTR) and a signal peptide sequence. A mouse cell or model capable of specifically interacting with an anti-human C1R antibody is successfully constructed.

The present application relates to a kind of based on logic gate double-target point chimeric antigen receptor modified TIL cell, lentivirus expression vector and application, belong to tumor immunotherapy and gene editing technical field.The TIL cell based on logic gate double-target point chimeric antigen receptor modified in the application, double-target point chimeric antigen receptor includes chimeric antigen receptor EGFR and chimeric antigen receptor GD2;Chimeric antigen receptor EGFR is composed of CD8 alpha signal peptide, anti-EGFR single-chain antibody, CD8 alpha transmembrane region, 4-1BB costimulatory domain and CD3 zeta intracellular signal domain in series;Chimeric antigen receptor GD2 is composed of CD8 alpha signal peptide, anti-GD2 single-chain antibody, CD28 transmembrane region, CD27 costimulatory domain and CD3 zeta intracellular signal domain in series.The present application solves the defects that lentivirus transduction targeting is poor in prior art, CAR signal activation specificity is insufficient, TIL cell is easily exhausted, has the advantages that gene integration is accurate, signal transduction is controllable, in-vivo survival time is long, can be efficiently used for the immunotherapy of double-antigen co-expression solid tumor.

This invention discloses an immune cell that secretes type 2 cytokines under hypoxic conditions and its applications, belonging to the fields of genetic engineering and cell engineering. The invention first constructs a nucleotide fragment encoding hypoxia-induced type 2 cytokines, including a signal peptide gene sequence, a CAR molecule nucleotide sequence targeting CD19 and CD22, and an IL-4 or IL-10 nucleotide sequence containing multiple HRE motifs of a hypoxia-inducible promoter. This nucleotide fragment is delivered to immune cells for stable expression, yielding an immune cell that secretes type 2 cytokines under hypoxic conditions. This immune cell secretes IL-4 or IL-10 only under hypoxic conditions, thereby leveraging the metabolic reprogramming effect of IL-4 or IL-10 on immune cells to enhance their activity under hypoxic conditions, thus achieving better long-term anti-tumor effects.

This invention discloses a lipophilic yeast strain for synthesizing astaxanthin (Yersinia lipophila). Yarrowia lipolytica This invention relates to an engineered strain, its construction method, and its application. The engineered strain is a *Yersinia lipolytica* strain carrying CrtZ and CrtW. The invention utilizes genetic engineering methods to introduce a *Yersinia lipolytica* strain derived from *Rhodochophora* into a β-carotene-producing strain via genetic engineering. Haematococcus Pluvialis The β-carotene hydroxylase encoding gene (HpCrtZ) originates from the genus Paracoccus ( Paracoccus sp. The gene encoding β-carotene ketolase (PsCrtW) and the gene derived from Saccharomyces cerevisiae (Saccharomyces cerevisiae) Saccharomyces cerevisiae The method involves obtaining a genetically engineered *Yersinia lipolytica* strain that produces astaxanthin by constructing a fusion enzyme complex and fusing it with peroxisomes, endoplasmic reticulum, and lipid droplet-targeting signal peptides to obtain a *Yersinia lipolytica* strain with higher astaxanthin yield. The astaxanthin-producing genetically engineered strain constructed in this invention achieved an astaxanthin yield of 1.43 g / L in a 5 L bioreactor after pH control and continuous feeding optimization.

The present invention relates to a plasmid that encodes a fusion protein comprising a signal peptide and the extracellular domain of the B-cell activating factor receptor (BAFF-R), and optionally, a fragment of the constant region (Fc) of an immunoglobulin. The invention also relates to compositions comprising said plasmid, and to the use of same in the treatment and / or prevention of inflammatory diseases in fish, more preferably in salmonids.

This invention discloses a highly efficient serine protease for degrading α-keratin, its degradation method, and its applications. The serine protease is named PliKerS, and its full-length amino acid sequence is shown in SEQ ID No. 2, with the corresponding coding gene sequence shown in SEQ ID No. 1. The amino acid sequence of the recombinant serine protease rPliKerS, which has its N-terminal signal peptide removed and a purification tag attached to its C-terminus, is shown in SEQ ID No. 4, with the corresponding coding gene sequence shown in SEQ ID No. 3. The recombinant serine protease rPliKerS degrades α-keratin under mild conditions, avoiding the environmental burden of strong alkaline treatment. It is particularly suitable for applications involving pet hair, hair waste, and leather pretreatment. The degradation products are soluble proteins and peptides, which can be used as high-value-added amino acid raw materials, functional peptide raw materials, biodegradable materials, bio-based material precursors, bio-feed proteins, fertilizers, etc., exhibiting high resource utilization value and promising industrial application prospects.

The application provides an engineered exosome loaded with a CD63 transmembrane domain-matrix metalloproteinase fusion protein and a preparation method and application thereof. The engineered exosome is secreted by a genetically engineered mesenchymal stem cell, has a CD63 derived transmembrane domain anchored on the membrane, and has a matrix metalloproteinase (MMP) loaded on the inner side of the membrane. The fusion protein comprises, from N-terminus to C-terminus, a fourth transmembrane domain and a C-terminal cytoplasmic tail of a human CD63 protein, a flexible linker peptide, and a human MMP without a natural signal peptide. The application realizes efficient and directional loading of MMPs by using a natural biological generation path of the exosome, shields the inhibition of MMPs by metalloproteinase tissue inhibitors in a scar tissue by using the membrane of the exosome, realizes specific activation of MMPs in a target cell, degrades abnormally deposited collagen, adjusts the ratio of type I and type III collagens, and plays an anti-fibrosis and anti-scar formation role. The application also provides a preparation method of the engineered exosome and application thereof in preparation of a medicine for preventing or treating pathological scars.

This invention discloses a Bacillus amyloliquefaciens strain expressing bovine lactoferrin, its construction method, and its applications, belonging to the field of bioengineering technology. This invention utilizes the highly efficient protein secretion capacity of Bacillus amyloliquefaciens NFΔSE and the constitutive expression vector pMA5 for recombinant expression of bovine lactoferrin. Further, extracellular secretory expression of lactoferrin is achieved through signal peptide screening, and efficient fermentation synthesis of lactoferrin is realized in a fermenter through strategies such as optimized combined nutrient conditions and enhanced iron supply. Compared to traditional extraction processes, this process can produce lactoferrin through fermentation using this recombinant strain, effectively improving lactoferrin production capacity and demonstrating good industrialization potential.

Provided herein are novel cell membrane targeting signal peptides, recombinant polypeptides comprising the signal peptides, nucleic acid molecules encoding the recombinant polypeptides, pharmaceutical compositions comprising the nucleic acid molecules, and methods of use thereof.

This article provides novel mitochondrial-targeting signal peptides, recombinant polypeptides containing them, nucleic acid molecules encoding them, pharmaceutical compositions containing them, and methods of use thereof.

The application belongs to the technical field of biological medicine and molecular biology, and particularly relates to a CAR-macrophage with enhanced efferocytosis targeting apoptotic cells and a preparation method and application thereof. The CAR provided by the application comprises a signal peptide segment, a ligand recognition domain, a tag gene, a hinge region, a transmembrane region and an intracellular signal domain, can recognize lipid or protein signals exposed on the surface of apoptotic cells in an inflammatory microenvironment, and realizes targeted phagocytosis and aggregation in an inflammatory area. DKP type unsaturated ionizable lipids have protonation characteristics in an acidic microenvironment, which helps mRNA encapsulation and endosome escape. Lipid nanoparticles contain CAR mRNA and can respond to broken surface ligands. Under inflammatory conditions, the ligands fall off to expose DOPS, thereby improving the endocytosis capacity of macrophages. The CAR-macrophage and the nanoparticles can be used to prepare drugs for treating diseases such as metabolic-associated fatty liver disease and atherosclerosis, realize multiple synergies, have high specificity and safety, and have good industrialization prospects.

The present application relates to the technical fields of biological medicine and cellular immunotherapy, and particularly relates to a signal conversion receptor targeting IL-10, an engineered macrophage and application thereof. The signal conversion receptor is composed of an extracellular domain and a transmembrane domain and an intracellular domain derived from TLR9, and the extracellular domain sequentially comprises a signal peptide, a HA tag and a specific binding domain of an IL-10 receptor alpha subunit from N-terminal to C-terminal. The present application further prepares an engineered macrophage SR CAR-M capable of specifically recognizing IL-10 and converting it into a TLR9 activation signal, which can induce macrophages to polarize to M1 type and has excellent phagocytosis and killing capacity for bladder cancer, breast cancer, lung cancer and melanoma cells, and can be used for preparing related tumor treatment drugs, overcoming the common problems of existing cell therapy, such as easy exhaustion, difficult infiltration and easy inhibition in solid tumors, and having significant clinical transformation potential.

This invention provides a virus-like particle vaccine gE-eVLP for varicella-zoster virus, a recombinant adenovirus vector vaccine, an mRNA vaccine, and their preparation methods and applications, belonging to the field of vaccine technology. The nucleotide sequence of the virus-like particle vaccine gE-eVLP provided by this invention includes a signal peptide sequence, a truncated and / or mutated sequence of the gE domain without the original signal peptide, and an EGE motif; the recombinant adenovirus vector vaccine and mRNA vaccine contain gE-eVLP. This invention innovatively integrates EABR self-assembled particle technology into the VZV adenovirus vector vaccine and mRNA vaccine technology platform, and systematically evaluates the immunogenicity of three novel vaccines: Ad26-tPA-gE-eVLP, AdC68-tPA-gE-eVLP, and LNP-tPA-gE-eVLP, providing important experimental evidence for the development of a new generation of highly effective and safe VZV vaccines.

This article provides novel recombinant peptides comprising endogenous signal peptides targeting cell membranes and payload proteins, nucleic acid molecules encoding said recombinant peptides, pharmaceutical compositions comprising said nucleic acid molecules, and methods of using them.

The present invention relates to the field of cell therapy. Disclosed are a fibroblast activation protein-targeting CAR T-cell, a preparation method therefor, and an application thereof. A CAR T-cell can be prepared by introducing an FAP-targeting chimeric antigen receptor (CAR) into a T lymphocyte, wherein the CAR in the CAR T-cell comprises a signal peptide, an antigen-binding domain, a hinge region, a transmembrane domain, a co-stimulatory signaling region, and a CD3 signaling domain. The CAR T-cell specifically recognizes the FAP by means of a single-chain variable fragment (scFv), which activates an intracellular signaling pathway, releasing cytokine IFN-γ, and exhibiting a cytotoxic effect on FAP+ cells, thereby achieving specific depletion of FAP+ cells at a lesion site. The CAR-T cell can be used for treating diseases characterized by upregulated FAP expression, such as fibrosis (pulmonary fibrosis, hepatic fibrosis, cardiac fibrosis, renal fibrosis, etc.), arthritis, autoimmune disorders (Crohn's disease, rheumatoid arthritis, etc.), and cardiovascular diseases, and demonstrates tremendous application potential and commercial value.

This article provides novel signal peptides for guiding encoded proteins to the endoplasmic reticulum of cells, recombinant polypeptides comprising said signal peptides, nucleic acid molecules encoding said recombinant polypeptides, pharmaceutical compositions comprising said nucleic acid molecules, and methods of using the same.

The application discloses a recombinant adenovirus shuttle plasmid and a preparation method thereof, a recombinant adenovirus and application thereof, and a Zika virus recombinant adenovirus plasmid, and belongs to the field of biological medicines. The Zika virus recombinant adenovirus shuttle plasmid provided by the application takes pShuttle as a carrier, carries a Zika virus E protein mutant gene, and the 5' end of the Zika virus E protein mutant gene is connected with a signal peptide gene; the 5' end of the signal peptide gene is connected with a Kozak sequence; and the 5' end of the Kozak sequence is connected with an enzyme cutting site 1. The recombinant shuttle plasmid, the recombinant plasmid and the recombinant adenovirus provided by the application can be applied to the preparation of a Zika virus adenovirus vaccine, and have wide development and application prospects.

This invention relates to the field of biomedical technology, and more particularly to a *Lactobacillus paracasei* strain with significant hypoglycemic effects. This invention develops an engineered bacterium that continuously secretes a mutant GLP-1 protein, capable of expressing a fusion peptide containing a signal peptide, an enhancing peptide, and the mutant GLP-1 protein. It exhibits good passage stability and can exert a dual therapeutic effect on type 2 diabetes through continuous secretion of the mutant GLP-1 protein and regulation of the gut microbiota. The engineered bacterium of this invention can be used to prepare oral pharmaceutical formulations. Therefore, this invention provides a new technical means for developing non-invasive, cost-effective, and efficient drug delivery strategies targeting GLP-1, and has broad application prospects.

The present invention relates to a polynucleotide molecule comprising a nucleotide sequence encoding a chimeric antigen receptor (CAR) or fragment thereof, said chimeric antigen receptor (CAR) or fragment thereof i) comprising an extracellular domain comprising an antigen binding region that binds to epidermal growth factor receptor variant III (EGFRvIII); or ii) comprising an extracellular domain comprising an antigen binding region that binds to CD19; wherein the nucleotide sequence encoding the CAR is operably linked to a promoter, and wherein the polynucleotide molecule further comprises a nucleotide sequence encoding a heterologous signal peptide fused to a signal regulatory protein gamma (SIRPy)-related protein (SGRP). The present invention further relates to a chimeric antigen receptor (CAR)-T cell expressing the polynucleotide molecule, as well as a method of treating cancer using said polynucleotide molecule and / or a chimeric antigen receptor (CAR)-T cell expressing said polynucleotide molecule.

This invention relates to the field of bioengineering technology, specifically to an endogenous signal peptide element fused with the MF-αpro region and its applications. The endogenous signal peptide element is composed of an endogenous signal peptide from Pichia pastoris with the C-terminus fused with MF-αpro or with amino acids 38 to 51 of the MF-αpro region detached; the amino acid sequence of the MF-αpro region is shown in SEQ ID NO:8; the amino acid sequence of the MF-αpro region with detached amino acids 38 to 51 is shown in SEQ ID NO:10. This invention provides a complete solution from rational screening to functional verification to element optimization. The resulting highly efficient, patent-free signal peptide element is suitable for the production of industrial enzymes, pharmaceutical proteins, and diagnostic reagents.

Provided herein are novel signal peptides that direct encoded proteins to cell junctions, recombinant polypeptides comprising the signal peptides, nucleic acid molecules encoding the recombinant polypeptides, pharmaceutical compositions comprising the nucleic acid molecules, and methods of use thereof.

The present application relates to a kind of pig alpha interferon mutant and its preparation method and application, the mutant amino acid sequence is as shown in SEQ ID NO.2.Preparation, with original PIFN-alpha gene as template, according to CHO-K1 cell codon bias optimization gene sequence, again with murine IGk signal peptide replaces traditional CHO signal peptide, while the glutamine of N-terminal 155th is replaced by the alanine with anti-degradation characteristics, by introducing N-terminal regular anti-degradation site to extend protein half-life, finally, the nucleotide sequence encoding the mutant is obtained by directional optimization.It is second, the present application is by constructing the recombinant expression vector pCHO1.0-PIFN-Bip containing double promoter synergistic expression system, and it is transferred into CHO cell and is expressed, successfully realize the efficient expression of pig alpha interferon in CHO cell, and it also has significant effect to be applied to the treatment of pig viral infectious disease.

The application provides a kind of genetic engineering exosome loaded with recombinant XVII type full-length human collagen and preparation and application, it is related to the field of bioengineering technology.The genetic engineering exosome provided by the application retains the intracellular domain, transmembrane domain, extracellular domain of XVII collagen completely, and also increases the exosome sorting signal peptide.The application also provides an extraction and separation method of the genetic engineering exosome loaded with recombinant XVII full-length human collagen and application in burn, scald, alopecia, oral ulcer and skin photoaging.The exosome prepared by the application is highly enriched with recombinant XVII type full-length human collagen on the exosome membrane, and retains the physiological activity of XVII type collagen, promotes the proliferation of epidermal cells, fibroblasts and hair follicle stem cells, plays the role of promoting re-epithelialization, promotes wound healing, promotes hair regeneration and delays skin aging.

The present disclosure provides a recombinant protein comprising a signal peptide, an S1 domain of a porcine epidemic diarrhea virus S protein, and a multimerization sequence. The present disclosure also provides a recombinant vaccine prepared from the recombinant protein, which has the advantages of higher safety, no reverse toxicity, stimulation of the body to produce an effective neutralizing antibody concentration, and batch production consistency.

Described herein are methods and compositions for producing heterologous proteins. Heterologous proteins can include sweet proteins and sweet polypeptides. For examples, described herein are expression cassettes, including, for example, promoters and signal peptides, for recombinantly expressing a recombinant sweet protein in a host cell.